Novo Nordisk’s weight-loss and diabetes drugs, Ozempic and Wegovy, are no longer in short supply, US regulators announced. The decision is expected to limit access to cheaper copies of the popular medications. Novo can now meet demand nationwide, indicating a stable supply and confidence from the company. This move puts Novo in a stronger position against US rival Eli Lilly & Co., boosting its competitiveness in the obesity treatment market. The Danish drugmaker’s investment in factory construction appears to be paying off, addressing the shortages that had plagued the medication.
Source: https://www.bloomberg.com/news/articles/2025-02-21/novo-s-ozempic-wegovy-shortage-ends-threatening-copycats